Design Therapeutics Inc. Common Stock (DSGN)
Stock · NASDAQ · Health Care
$15.11as of 8/28/2026
Price chart
Open in TradingViewActive signals
Support level
$9.9
Industry
Biotechnology: Pharmaceutical Preparations
About DSGN
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifyin…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 55
- Website
- www.designtx.com/
Fundamentals
- 1-day range
- $14.8$15.36
- Market cap
- $796.95M
- P/E (trailing)
- —
- P/E (forward)
- -9.49
- EPS (trailing)
- $-1.18
- Dividend yield
- —
- Beta
- 1.66
- Avg. volume
- 706.9K
52-week range
$5.04$17.25
Next earnings: November 5, 2026 · EPS estimate $-0.35confirmed
Forecasts
6 analyst ratings
Buy 92%
Hold 8%
Sell 0%
1-year price forecast
High
$22
+45.6%
Median
$21
+39.0%
Low
$20
+32.4%
Design Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- DSGNDesign Therapeutics Inc. Common Stock$15.12▼ 0.85%Market cap $796.95MP/E —$5.04$17.25
- GERNGeron Corporation Common Stock$1.51▼ 1.63%Market cap $821.15MP/E —$1.04$2.01
- ACRSAclaris Therapeutics Inc. Common Stock$6.01▼ 2.44%Market cap $772.34MP/E —$1.74$6.6
- PHARPharming Group N.V. ADS each representing 10 ordinary shares$11.7▼ 0.68%Market cap $766.28MP/E 88.15$0.8338$1.82
- MNPRMonopar Therapeutics Inc. Common Stock$112.17▼ 1.55%Market cap $747.88MP/E —$32.77$124.82
- ANNXAnnexon Inc. Common Stock$4.97▼ 5.33%Market cap $860.17MP/E —$2.03$7.18
- DRUGBright Minds Biosciences Inc. Common Stock$72.74▼ 2.41%Market cap $723.93MP/E —$53.99$170
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| DSGN Design Therapeutics Inc. Common Stock | $796.95M | — | $15.12 | ▼ 0.85% | $5.04$17.25 |
| GERN Geron Corporation Common Stock | $821.15M | — | $1.51 | ▼ 1.63% | $1.04$2.01 |
| ACRS Aclaris Therapeutics Inc. Common Stock | $772.34M | — | $6.01 | ▼ 2.44% | $1.74$6.6 |
| PHAR Pharming Group N.V. ADS each representing 10 ordinary shares | $766.28M | 88.15 | $11.7 | ▼ 0.68% | $0.8338$1.82 |
| MNPR Monopar Therapeutics Inc. Common Stock | $747.88M | — | $112.17 | ▼ 1.55% | $32.77$124.82 |
| ANNX Annexon Inc. Common Stock | $860.17M | — | $4.97 | ▼ 5.33% | $2.03$7.18 |
| DRUG Bright Minds Biosciences Inc. Common Stock | $723.93M | — | $72.74 | ▼ 2.41% | $53.99$170 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Marvell Technology, PayPal, Rubrik And Other Big Stocks Moving Lower In Friday’s Pre-Market SessionBenzinga · 8/28/2026
- Design Therapeutics Q2 EPS $(0.32) Beats $(0.34) EstimateBenzinga · 8/3/2026
Insider Activity
Insider Actions →Acquired
247.5K
Disposed
0
- Gover Justin D. · June 9, 2026 · Grant30.0K
- Berger Heather A. · June 9, 2026 · Grant30.0K
- George Simeon · June 9, 2026 · Grant30.0K
- LAPPE RODNEY W · June 9, 2026 · Grant30.0K
- Shapiro David · June 9, 2026 · Grant30.0K
- John P. Schmid · June 9, 2026 · Grant30.0K
- Shapiro David · March 31, 2026 · Grant7.5K
- Shapiro David · March 31, 2026 · Grant60.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 37.63M
- Total value held
- $391.38M
- Institutional holders
- 121
Top holders this quarter
- Unknown6.53M
- Unknown2.97M
- Unknown2.72M
- Unknown2.59M
- Unknown2.13M
- Unknown1.95M
- Unknown1.74M
- Unknown1.61M
- Unknown1.53M
- Unknown1.35M
See the full, filterable feed with live charts on the MarketWall dashboard.